Member Info for Wiggly

.

The fact DR FM is presenting and Avacta are sponsoring (!) tells me all I need to know about how the trial is progressing.

We know all about the pre clinical data and are all waiting to hear whether that is replicated in human. Pre clinical was presented in USA few months back. Why would they chose to present again after dosing 4 cohorts?

Why would Avacta sponsor this event to present only the pre clinical data ?

You don't sponsor an event you are not ready to talk at.

Ask yourself the following question;

Would Avacta (and Point) sponsor an event such as this if preCISION was not working? The answer is obviously a resounding no.

I think we can conclude that preCISION (Fap activation) is working, which translates as CHEMO with vastly reduced side effects, which, without ramping too much, translates into a share price many many multiples of 140p.

So... SOFIE, POINT AND AVACTA are the key sponsors sponsoring this FIRST EVENT OF ITS KIND.

This is just nuts. It is now obvious they are gearing up to make a KEY announcement at this event!!!

Sofie = Main

Point = Gold

Avacta = Silver

https://icpo-forum.org/sponsors-list.html

In this FIRST EVENT OF ITS KING, the ICPO Foundation has assembled a world-class scientific program and invited representatives from academia and industry to dive deep into FAP, its history and role in biology of disease, current research, and future applications.

Besides whether you are very familiar with FAP or simply curious as to how this buzzed-about target may potentially impact the field of medicine, this Theranostics FAP Summit will be of benefit to you and allow you to raise questions in an interactive way.

Avacta are about to announce Chemo without (or with vastly reduced) side effects But I really think that they are!

£10-£20-£30 per share would all look cheap upon such an announcement!

It certainly works. This is DR FM our CSO making these statements, not the CEO who may have alternative motives.

There certainly is. MM will take everything at 133

Whether Dr FM will present the pre-clinical (I highly doubt at this stage) or partial clinical data (too good an opportunity not to disclose some clinical data IMO) There is absolutely no way DR Fiona McLaughlin agrees to present at this event if she is in any doubt about the preCISION technology!

If Avacta want to shine a massive spotlight on PreCISION then this is a great opportunity to do so.. and might warrant release if an RNS prior to Saturday (assuming they want to disclose some non-public information).

Fiona will be delivering a key update on Avacta Therapeutics’ lead pre|CISION™ programme, AVA6000 – a tumour-activated form of doxorubicin – on Sat 5th Nov

Like the cat is out of the bag!

Considering that AS was not sure there would be a cohort 4 I think a cohort 5 is unlikely (not impossible though)

Pl,

The CB Funded the acquisition. There was no immediate need to raise additional via the placing.

Im not sure regarding the legality. I don't think it would be legal to raise at 95p while in knowledge of news that would materially impact the company valuation to the downside.

The Company consulted with a number of its major shareholders prior to the Placing and is pleased by the support it has received from both existing and new shareholders.

I'm sure these major holders were given some guidance from AS related to AVA6K. It certainly would have been my first question to AS prior to offering more cash, at next to no discount Vs current market price...

Offering standard guidance such as 'progressing well' 'data consistent' 'very pleased with progress' is significant at this stage of the trial, particularly with biopsy data in hand!

AS on record stating 'very confident' we will have biopsy data included within the phase 1a read out... With Cohort 4 now complete, we must surely already have the biopsy data, which means it must be positive biopsy data... otherwise it would be impossible for avacta to raise without disclosure.

Positive safety data coupled with biopsy data confirming activation and we are going to explode upwards.

Can't imagine the new and existing II that supported the placing at 95p would be very happy if Avacta released news next week that negatively impacted the share price...

Can't imagine Heights Capital would be pleased either...

Do you think the placing and open offer is a thank you gesture from the BOD to loyal shareholders prior to issue of major news?

From a legal perspective, would Avacta have been able to place while in knowledge that the clinical data (inc biopsies) was not aligned with the pre clinical data? This is an important point imo. We invest on the theory that AVA6k will perform in human as it did in mice and if Avacta are in knowledge that this is not the case surely they can't raise without full disclosure!

Has commenced